Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Metabolomics.

Gooding JR, Agrawal S, McRitchie S, Acuff Z, Merchant ML, Klein JB, Smoyer WE, Sumner SJ; Midwest Pediatric Nephrology Consortium.

Kidney Int Rep. 2019 Sep 19;5(1):81-93. doi: 10.1016/j.ekir.2019.09.010. eCollection 2020 Jan.

2.

Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics.

Agrawal S, Merchant ML, Kino J, Li M, Wilkey DW, Gaweda AE, Brier ME, Chanley MA, Gooding JR, Sumner SJ, Klein JB, Smoyer WE; Midwest Pediatric Nephrology Consortium.

Kidney Int Rep. 2019 Sep 19;5(1):66-80. doi: 10.1016/j.ekir.2019.09.009. eCollection 2020 Jan.

3.

Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research.

Denburg MR, Razzaghi H, Bailey LC, Soranno DE, Pollack AH, Dharnidharka VR, Mitsnefes MM, Smoyer WE, Somers MJG, Zaritsky JJ, Flynn JT, Claes DJ, Dixon BP, Benton M, Mariani LH, Forrest CB, Furth SL.

J Am Soc Nephrol. 2019 Dec;30(12):2427-2435. doi: 10.1681/ASN.2019040365. Epub 2019 Nov 15.

PMID:
31732612
4.

Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.

Hari P, Khandelwal P, Smoyer WE.

Pediatr Nephrol. 2019 Jul 13. doi: 10.1007/s00467-019-04301-y. [Epub ahead of print]

PMID:
31302760
5.

Rituximab Use in the Management of Childhood Nephrotic Syndrome.

Kallash M, Smoyer WE, Mahan JD.

Front Pediatr. 2019 May 10;7:178. doi: 10.3389/fped.2019.00178. eCollection 2019. Review.

6.

Health-related quality of life in glomerular disease.

Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, Cai Y, Davis TK, Fernandez H, Fornoni A, Gbadegesin RA, Herreshoff E, Mahan JD, Nachman PH, Selewski DT, Sethna CB, Srivastava T, Tuttle KR, Wang CS, Falk RJ, Gharavi AG, Gillespie BW, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Guay-Woodford LM, Reeve B, Gipson DS; CureGN Consortium.

Kidney Int. 2019 May;95(5):1209-1224. doi: 10.1016/j.kint.2018.12.018. Epub 2019 Feb 27.

PMID:
30898342
7.

"Learn From Every Patient": How a Learning Health System Can Improve Patient Care.

Noritz G, Boggs A, Lowes LP, Smoyer WE.

Pediatr Qual Saf. 2018 Sep 5;3(5):e100. doi: 10.1097/pq9.0000000000000100. eCollection 2018 Sep-Oct.

8.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

9.

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium.

Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9.

PMID:
30420158
10.

Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome.

Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN.

Pediatr Nephrol. 2019 Feb;34(2):261-267. doi: 10.1007/s00467-018-4072-6. Epub 2018 Sep 7.

11.

Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Sargel CL, Aboud M, Forster A, Langman LJ, Tansmore J, Mueller BA, Smoyer WE, Auletta JJ.

J Pediatr Pharmacol Ther. 2018 Jul-Aug;23(4):337-342. doi: 10.5863/1551-6776-23.4.337.

12.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2017 Dec 13;14(1):70. doi: 10.1038/nrneph.2017.175.

PMID:
29234164
13.

Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.

Nie X, Chanley MA, Pengal R, Thomas DB, Agrawal S, Smoyer WE.

Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F602-F613. doi: 10.1152/ajprenal.00207.2017. Epub 2017 Nov 29.

14.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2018 Jan;14(1):57-70. doi: 10.1038/nrneph.2017.155. Epub 2017 Nov 27. Review. Erratum in: Nat Rev Nephrol. 2017 Dec 13;14 (1):70.

15.

Enhancing clinical trial development for pediatric kidney diseases.

Schnaper HW, Flynn JT, Gross C, Cropp AB, Dehmel B, Patel LB, Greenbaum LA, Houtsmuller E, Kaskel F, Moxey-Mims M, Nowak K, Silverstein D, Thompson A, Yao L, Darsey E, Smoyer WE.

Pediatr Res. 2017 Nov;82(5):727-732. doi: 10.1038/pr.2017.180. Epub 2017 Aug 30. Review.

16.

Role of albumin and its modifications in glomerular injury.

Agrawal S, Smoyer WE.

Pflugers Arch. 2017 Aug;469(7-8):975-982. doi: 10.1007/s00424-017-2029-4. Epub 2017 Jul 22. Review.

PMID:
28735420
17.

Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Sharma R, Waller AP, Agrawal S, Wolfgang KJ, Luu H, Shahzad K, Isermann B, Smoyer WE, Nieman MT, Kerlin BA.

J Am Soc Nephrol. 2017 Sep;28(9):2618-2630. doi: 10.1681/ASN.2016070789. Epub 2017 Apr 19.

18.

Creating Local Learning Health Systems: Think Globally, Act Locally.

Smoyer WE, Embi PJ, Moffatt-Bruce S.

JAMA. 2016 Dec 20;316(23):2481-2482. doi: 10.1001/jama.2016.16459. No abstract available.

PMID:
27997662
19.

Glomerular Diseases: Registries and Clinical Trials.

Moxey-Mims MM, Flessner MF, Holzman L, Kaskel F, Sedor JR, Smoyer WE, Thompson AM, Yao L.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2234-2243. Epub 2016 Sep 26.

20.

'Learn From Every Patient': implementation and early results of a learning health system.

Lowes LP, Noritz GH, Newmeyer A, Embi PJ, Yin H, Smoyer WE; ‘Learn from Every Patient’ Study Group.

Dev Med Child Neurol. 2017 Feb;59(2):183-191. doi: 10.1111/dmcn.13227. Epub 2016 Aug 22.

21.

Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?

Zea AH, Stewart T, Ascani J, Tate DJ, Finkel-Jimenez B, Wilk A, Reiss K, Smoyer WE, Aviles DH.

PLoS One. 2016 Jul 7;11(7):e0157907. doi: 10.1371/journal.pone.0157907. eCollection 2016.

22.

Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.

Agrawal S, Chanley MA, Westbrook D, Nie X, Kitao T, Guess AJ, Benndorf R, Hidalgo G, Smoyer WE.

Sci Rep. 2016 May 4;6:24392. doi: 10.1038/srep24392.

23.

"Saving Young Lives" with acute kidney injury: the challenge of acute dialysis in low-resource settings.

Smoyer WE, Finkelstein FO, McCulloch MI, Carter M, Brusselmans A, Feehally J.

Kidney Int. 2016 Feb;89(2):254-6. doi: 10.1016/j.kint.2015.10.009. No abstract available.

PMID:
26806823
24.

Saving Young Lives: provision of acute dialysis in low-resource settings.

Smoyer WE, Finkelstein FO, McCulloch M, Carter M, Brusselmans A, Feehally J.

Lancet. 2015 Nov 21;386(10008):2056. doi: 10.1016/S0140-6736(15)00971-X. Epub 2015 Nov 20. No abstract available.

PMID:
26700390
25.

AKI in Children Hospitalized with Nephrotic Syndrome.

Rheault MN, Zhang L, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'Alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Carpenter SL, Kerlin BA, Smoyer WE; Midwest Pediatric Nephrology Consortium.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2110-8. doi: 10.2215/CJN.06620615. Epub 2015 Oct 8.

26.

Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE.

J Am Soc Nephrol. 2015 Dec;26(12):3009-19. doi: 10.1681/ASN.2014111097. Epub 2015 Apr 8.

27.

Sponsors meet scientists to speed pediatric medicines development.

Davis JM, Smoyer WE, Connor EM, Huskins WC, Pastern C, Purucker M, Schrader EC, Jackson CR, Kaskel FJ, Hirschfeld S.

Sci Transl Med. 2015 Mar 18;7(279):279fs11. doi: 10.1126/scitranslmed.aaa2045.

28.

Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study.

Kerlin BA, Stephens JA, Hogan MJ, Smoyer WE, O'Brien SH.

Pediatr Res. 2015 Mar;77(3):463-71. doi: 10.1038/pr.2014.198. Epub 2014 Dec 17.

29.

Healthcare burden of venous thromboembolism in childhood chronic renal diseases.

Kerlin BA, Smoyer WE, Tsai J, Boulet SL.

Pediatr Nephrol. 2015 May;30(5):829-37. doi: 10.1007/s00467-014-3008-z. Epub 2014 Dec 7.

30.

Hemodialysis for near-fatal sodium phosphate toxicity in a child receiving sodium phosphate enemas.

Becknell B, Smoyer WE, O'Brien NF.

Pediatr Emerg Care. 2014 Nov;30(11):814-7. doi: 10.1097/PEC.0000000000000267.

PMID:
25373567
31.

HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome.

Gbadegesin RA, Adeyemo A, Webb NJ, Greenbaum LA, Abeyagunawardena A, Thalgahagoda S, Kale A, Gipson D, Srivastava T, Lin JJ, Chand D, Hunley TE, Brophy PD, Bagga A, Sinha A, Rheault MN, Ghali J, Nicholls K, Abraham E, Janjua HS, Omoloja A, Barletta GM, Cai Y, Milford DD, O'Brien C, Awan A, Belostotsky V, Smoyer WE, Homstad A, Hall G, Wu G, Nagaraj S, Wigfall D, Foreman J, Winn MP; Mid-West Pediatric Nephrology Consortium.

J Am Soc Nephrol. 2015 Jul;26(7):1701-10. doi: 10.1681/ASN.2014030247. Epub 2014 Oct 27.

32.

Peritoneal dialysis, acute kidney injury, and the Saving Young Lives program.

Finkelstein FO, Smoyer WE, Carter M, Brusselmans A, Feehally J.

Perit Dial Int. 2014 Jul-Aug;34(5):478-80. doi: 10.3747/pdi.2014.00041. No abstract available.

33.

Albumin-induced podocyte injury and protection are associated with regulation of COX-2.

Agrawal S, Guess AJ, Chanley MA, Smoyer WE.

Kidney Int. 2014 Dec;86(6):1150-60. doi: 10.1038/ki.2014.196. Epub 2014 Jun 11.

34.

Meeting the demand for pediatric clinical trials.

Connor EM, Smoyer WE, Davis JM, Zajicek A, Ulrich L, Purucker M, Hirschfeld S.

Sci Transl Med. 2014 Mar 12;6(227):227fs11. doi: 10.1126/scitranslmed.3008043.

35.

The CTSA mentored career development program: supporting the careers of child health investigators.

Byington CL, Higgins S, Kaskel FJ, Purucker M, Davis JM, Smoyer WE.

Clin Transl Sci. 2014 Feb;7(1):44-7. doi: 10.1111/cts.12122. Epub 2013 Nov 8.

36.

Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome.

Rheault MN, Wei CC, Hains DS, Wang W, Kerlin BA, Smoyer WE.

Pediatr Nephrol. 2014 Jan;29(1):139-47. doi: 10.1007/s00467-013-2607-4. Epub 2013 Sep 14.

37.

Venous thromboembolism in pediatric nephrotic syndrome.

Kerlin BA, Haworth K, Smoyer WE.

Pediatr Nephrol. 2014 Jun;29(6):989-97. doi: 10.1007/s00467-013-2525-5. Epub 2013 Jun 28. Review.

38.

Nephrotic syndrome: Genetic screening in steroid-resistant nephrotic syndrome.

Mak RH, Smoyer WE.

Nat Rev Nephrol. 2013 Jul;9(7):379-81. doi: 10.1038/nrneph.2013.101. Epub 2013 May 21. No abstract available.

PMID:
23689120
39.

Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium.

Straatmann C, Ayoob R, Gbadegesin R, Gibson K, Rheault MN, Srivastava T, Tran CL, Gipson DS, Greenbaum LA, Smoyer WE, Vehaskari VM.

Pediatr Nephrol. 2013 Aug;28(8):1235-41. doi: 10.1007/s00467-013-2483-y. Epub 2013 Apr 30.

PMID:
23633037
40.

Crucial roles of the protein kinases MK2 and MK3 in a mouse model of glomerulonephritis.

Guess AJ, Ayoob R, Chanley M, Manley J, Cajaiba MM, Agrawal S, Pengal R, Pyle AL, Becknell B, Kopp JB, Ronkina N, Gaestel M, Benndorf R, Smoyer WE.

PLoS One. 2013;8(1):e54239. doi: 10.1371/journal.pone.0054239. Epub 2013 Jan 23.

41.

Genetic testing in nephrotic syndrome--challenges and opportunities.

Gbadegesin RA, Winn MP, Smoyer WE.

Nat Rev Nephrol. 2013 Mar;9(3):179-84. doi: 10.1038/nrneph.2012.286. Epub 2013 Jan 15. Review.

42.

A new 'tac' for childhood nephrotic syndrome.

Becknell B, Greenbaum LA, Smoyer WE.

Kidney Int. 2012 Nov;82(10):1049-51. doi: 10.1038/ki.2012.272.

43.

Trends in pediatric primary membranoproliferative glomerulonephritis costs and complications.

Wei CC, Wang W, Smoyer WE, Licht C.

Pediatr Nephrol. 2012 Dec;27(12):2243-50. doi: 10.1007/s00467-012-2249-y. Epub 2012 Jul 18.

PMID:
22802081
44.

Trends in hospitalization characteristics for pediatric nephrotic syndrome in the USA.

Ayoob RM, Hains DS, Smoyer WE.

Clin Nephrol. 2012 Aug;78(2):106-11.

PMID:
22790454
45.

Childhood nephrotic syndrome--current and future therapies.

Greenbaum LA, Benndorf R, Smoyer WE.

Nat Rev Nephrol. 2012 Jun 12;8(8):445-58. doi: 10.1038/nrneph.2012.115. Review.

PMID:
22688744
46.

Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.

Kerlin BA, Ayoob R, Smoyer WE.

Clin J Am Soc Nephrol. 2012 Mar;7(3):513-20. doi: 10.2215/CJN.10131011. Epub 2012 Feb 16. Review.

47.

Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects.

Agrawal S, Guess AJ, Benndorf R, Smoyer WE.

Mol Pharmacol. 2011 Sep;80(3):389-99. doi: 10.1124/mol.111.071654. Epub 2011 Jun 2.

48.

Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury.

Pengal R, Guess AJ, Agrawal S, Manley J, Ransom RF, Mourey RJ, Benndorf R, Smoyer WE.

Am J Physiol Renal Physiol. 2011 Sep;301(3):F509-19. doi: 10.1152/ajprenal.00661.2010. Epub 2011 May 25.

49.

Do declining private insurance coverage rates influence pediatric hospital charging practices?

Hains DS, Reagan PB, Smoyer WE.

Clin Pediatr (Phila). 2011 May;50(5):417-23. doi: 10.1177/0009922810393498. Epub 2011 Feb 27.

PMID:
21357198
50.

Dose- and time-dependent glucocorticoid receptor signaling in podocytes.

Guess A, Agrawal S, Wei CC, Ransom RF, Benndorf R, Smoyer WE.

Am J Physiol Renal Physiol. 2010 Oct;299(4):F845-53. doi: 10.1152/ajprenal.00161.2010. Epub 2010 Jul 14.

Supplemental Content

Loading ...
Support Center